Medicina
Departamento
Pfizer (United States)
Nueva York, Estados UnidosPublicaciones en colaboración con investigadores/as de Pfizer (United States) (105)
2024
-
Cost-Effectiveness Analysis of Abrocitinib Compared with Other Systemic Treatments for Severe Atopic Dermatitis in Spain
PharmacoEconomics - Open, Vol. 8, Núm. 2, pp. 291-302
-
Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study
European Journal of Cancer, Vol. 196
2023
-
Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Clinical Cancer Research, Vol. 29, Núm. 20, pp. 4166-4177
-
CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 8, pp. 1557-1568
-
Development of a predictive model of venous thromboembolism recurrence in anticoagulated cancer patients using machine learning
Thrombosis Research, Vol. 228, pp. 181-188
-
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Nature Medicine, Vol. 29, Núm. 9, pp. 2259-2267
-
Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial
Clinical and Translational Oncology
-
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
Rheumatology and Therapy, Vol. 10, Núm. 2, pp. 357-373
-
Preference of acromegaly patients for treatment attributes in Spain
Endocrine, Vol. 82, Núm. 2, pp. 379-389
-
The role of diagnostic tests in antifungal stewardship for treating invasive fungal infections: A plain language summary
Future Microbiology, Vol. 18, Núm. 1, pp. 9-13
2022
-
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 3, pp. 282-293
-
Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study
Clinical Genitourinary Cancer, Vol. 20, Núm. 1, pp. 25-34
-
Comorbidity identification and referral in atopic dermatitis: a consensus document
Journal of Dermatological Treatment, Vol. 33, Núm. 5, pp. 2643-2653
-
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib
npj Precision Oncology, Vol. 6, Núm. 1
-
Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain
Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 22, Núm. 1, pp. 73-83
-
Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain
Journal of Medical Economics, Vol. 25, Núm. 1, pp. 840-847
-
Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer
Clinical Cancer Research, Vol. 28, Núm. 7, pp. 1383-1390
-
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies
RMD open, Vol. 8, Núm. 1
-
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study
European Journal of Cancer, Vol. 168, pp. 12-24
-
Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC
ESMO Open, Vol. 7, Núm. 3